BioCentury | Sep 29, 2020
Management Tracks

Garijo picked to succeed Oschmann at Merck KGaA; plus BioShin, Abeona, Rubius, Nimbus, Vizgen

...life science, respectively. Guenter, who will be located in Darmstadt, Germany, has been CEO of Almirall S.A....
BioCentury | Jan 22, 2020
Company News

Despite outreach to over 18 companies, Lilly was only biopharma to offer Dermira takeout

...contacted Lilly in August 2018; however, preliminary discussions led nowhere. The next February, Dermira granted Almirall S.A....
BioCentury | Oct 19, 2019
Clinical News

Dermira data could bolster bid as Dupixent alternative

...four weeks; top-line data from the induction period are due in 1H21. The company granted Almirall S.A....
BioCentury | Aug 21, 2019
Distillery Therapeutics

Targeting CAD or DHODH to inhibit pyrimidine synthesis for glioblastoma

...DHODH inhibitors Aubagio and Arava lefunomide for multiple sclerosis (MS) and rheumatoid arthritis (RA), respectively. Almirall S.A....
BioCentury | Jul 12, 2019
Financial News

HitGen joins growing Shanghai IPO queue

...formed more than 60 partnerships, including deals this year with Gilead Sciences Inc. (NASDAQ:GILD) and Almirall S.A....
...Board" ). Targets: HDAC1 - Histone deacetylase 1; HDAC2 - Histone deacetylase 2 Hongjiang Li, Staff Writer HG146 Almirall S.A. Gilead...
BioCentury | Jun 26, 2019
Company News

June 25 Company Quick Takes: Conatus restructuring; plus Almirall-Dermira, Acer, Glenmark and more

...After NASH Therapy Misses Fibrosis Endpoint” ). Almirall exercises European option for Dermira’s dermatitis candidate Almirall S.A....
...tnx-650, anti-IL13) Ryaltris, mometasone/olopatadine (gsp 301) Seven-day contraceptive patch, Twirla (AG200-15, ag-200-15, Agile Patch, estradiol/levonorgestrel) Agile Therapeutics Agile Therapeutics Inc. Almirall Almirall S.A. Conatus Conatus...
BioCentury | Jun 26, 2019
Distillery Therapeutics

Induction of NFE2L2 activity for Alzheimer's disease

...and memory and decreased levels of neurotoxic β amyloid and phosphorylated tau in brain tissue. Almirall S.A....
BioCentury | Jun 20, 2019
Targets & Mechanisms

Moving beyond the active site: why allostery is newly in fashion

...later development activities for the program. Preclinical $50 $550 July 2018 Evotec SE (Xetra:EVT) / Almirall S.A....
BioCentury | Jun 2, 2019
Company News

Aslan’s change of course on eczema asset brings flexibility for future deals

...to include full commercial rights. It has renegotiated deals with Array BioPharma Inc. (NASDAQ:ARRY) and Almirall S.A....
BioCentury | May 20, 2019
Distillery Therapeutics

Aubagio and other DHODH inhibitors as epilepsy therapies

...multiple sclerosis (MS). Sanofi also markets the DHODH inhibitor Arava lefunomide for rheumatoid arthritis (RA). Almirall S.A....
Items per page:
1 - 10 of 350
BioCentury | Sep 29, 2020
Management Tracks

Garijo picked to succeed Oschmann at Merck KGaA; plus BioShin, Abeona, Rubius, Nimbus, Vizgen

...life science, respectively. Guenter, who will be located in Darmstadt, Germany, has been CEO of Almirall S.A....
BioCentury | Jan 22, 2020
Company News

Despite outreach to over 18 companies, Lilly was only biopharma to offer Dermira takeout

...contacted Lilly in August 2018; however, preliminary discussions led nowhere. The next February, Dermira granted Almirall S.A....
BioCentury | Oct 19, 2019
Clinical News

Dermira data could bolster bid as Dupixent alternative

...four weeks; top-line data from the induction period are due in 1H21. The company granted Almirall S.A....
BioCentury | Aug 21, 2019
Distillery Therapeutics

Targeting CAD or DHODH to inhibit pyrimidine synthesis for glioblastoma

...DHODH inhibitors Aubagio and Arava lefunomide for multiple sclerosis (MS) and rheumatoid arthritis (RA), respectively. Almirall S.A....
BioCentury | Jul 12, 2019
Financial News

HitGen joins growing Shanghai IPO queue

...formed more than 60 partnerships, including deals this year with Gilead Sciences Inc. (NASDAQ:GILD) and Almirall S.A....
...Board" ). Targets: HDAC1 - Histone deacetylase 1; HDAC2 - Histone deacetylase 2 Hongjiang Li, Staff Writer HG146 Almirall S.A. Gilead...
BioCentury | Jun 26, 2019
Company News

June 25 Company Quick Takes: Conatus restructuring; plus Almirall-Dermira, Acer, Glenmark and more

...After NASH Therapy Misses Fibrosis Endpoint” ). Almirall exercises European option for Dermira’s dermatitis candidate Almirall S.A....
...tnx-650, anti-IL13) Ryaltris, mometasone/olopatadine (gsp 301) Seven-day contraceptive patch, Twirla (AG200-15, ag-200-15, Agile Patch, estradiol/levonorgestrel) Agile Therapeutics Agile Therapeutics Inc. Almirall Almirall S.A. Conatus Conatus...
BioCentury | Jun 26, 2019
Distillery Therapeutics

Induction of NFE2L2 activity for Alzheimer's disease

...and memory and decreased levels of neurotoxic β amyloid and phosphorylated tau in brain tissue. Almirall S.A....
BioCentury | Jun 20, 2019
Targets & Mechanisms

Moving beyond the active site: why allostery is newly in fashion

...later development activities for the program. Preclinical $50 $550 July 2018 Evotec SE (Xetra:EVT) / Almirall S.A....
BioCentury | Jun 2, 2019
Company News

Aslan’s change of course on eczema asset brings flexibility for future deals

...to include full commercial rights. It has renegotiated deals with Array BioPharma Inc. (NASDAQ:ARRY) and Almirall S.A....
BioCentury | May 20, 2019
Distillery Therapeutics

Aubagio and other DHODH inhibitors as epilepsy therapies

...multiple sclerosis (MS). Sanofi also markets the DHODH inhibitor Arava lefunomide for rheumatoid arthritis (RA). Almirall S.A....
Items per page:
1 - 10 of 350